- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to...

JERUSALEM, November 13th, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...

JERUSALEM, October 21, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...

first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.

Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this...

JERUSALEM, August 2 2 , 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...

- First patient treated in May for liver metastases from colorectal cancer -   - Publication in June in Cancers journal of long-term...

https://www.msn.com/en-us/health/other/emory-doctor-hopeful-about-clinical-trial-for-new-skin-cancer-treatment/ar-BB1oTdCU?ocid=BingNewsVerp

Xcurespodcast

The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin,...